title: PET imaging of amyloid deposition in patients with mild cognitive impairment.
abstract: It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3+/-7.8 (S.D.) years) underwent PET studies with (11)C-PIB, and (18)F-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, as well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively, were used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later at clinical follow-up converted to AD (8.1+/-6.0 (S.D.) months) showed significant higher PIB retention compared to non-converting MCI patients and HC, respectively (ps<0.01). The PIB retention in MCI converters was comparable to AD patients (p>0.01). Correlations were observed in the MCI patients between PIB retention and CSF Abeta(1-42), total Tau and episodic memory, respectively.
authors.affiliation: Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden.
authors.forename: Anton
authors.initials: A
authors.lastname: Forsberg
authors.forename: Henry
authors.initials: H
authors.lastname: Engler
authors.forename: Ove
authors.initials: O
authors.lastname: Almkvist
authors.forename: Gunnar
authors.initials: G
authors.lastname: Blomquist
authors.forename: Göran
authors.initials: G
authors.lastname: Hagman
authors.forename: Anders
authors.initials: A
authors.lastname: Wall
authors.forename: Anna
authors.initials: A
authors.lastname: Ringheim
authors.forename: Bengt
authors.initials: B
authors.lastname: Långström
authors.forename: Agneta
authors.initials: A
authors.lastname: Nordberg
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism / Q000473:pathology; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000814:Aniline Compounds; D052160:Benzothiazoles; D002540:Cerebral Cortex / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000503:physiopathology; D003072:Cognition Disorders / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000503:physiopathology; D018450:Disease Progression; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D058225:Plaque, Amyloid / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology*; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011379:Prognosis; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D052160:Benzothiazoles; D013844:Thiazoles; D019788:Fluorodeoxyglucose F18; D005947:Glucose